Sarepta exchanges $291.4M of 1.25% notes for 4.875% notes due 2030 plus $31.6M cash

Sarepta Therapeutics, Inc.

Exchanged ~$291.4M of existing 1.25% Convertible Senior Notes due 2027 for new 4.875% Convertible Notes due 2030 plus ~$31.6M cash.
New notes issued as additional notes under August 2025 indenture; total 4.875% notes now ~$893.4M outstanding.
Exchange involved holders including entity affiliated with board member Michael Chambers.
Transaction closed December 18, 2025; extends maturity from 2027 to 2030 at higher coupon.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Sarepta Therapeutics, Inc. incurred convertible notes of approximately $291.4 million with certain holders (including Michael A. Chambers Living Trust) at 4.875% maturing due 2030.

Instrument: convertible notes
Principal: approximately $291.4 million
Counterparty: certain holders (including Michael A. Chambers Living Trust)
Rate: 4.875%
Maturity: due 2030
Event: incurrence

Exact text from the filing

the holders party thereto agreed to exchange with the Company approximately $291.4 million in aggregate principal amount of Existing Convertible Notes held by them for consideration consisting of (i) approximately $291.4 million in aggregate principal amount of 4.875% Convertible Senior Notes due 2030 (the “New Convertible Notes”) and (ii) an aggregate of approximately $31.6 million in cash.

View on SEC.gov

309 debt financings filed in the last 30 days. Browse all debt financings →

Sarepta Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-326969

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.